Jazz Pharmaceuticals PLC

18 sept. 2026, 20:06 UTC

Jazz Pharmaceuticals PLC shares fell sharply, reaching a session low amid broader market performance challenges and remaining below its 20-day moving average.

17 sept. 2026, 20:13 UTC

Jazz Pharmaceuticals PLC saw a modest decline during after-market hours on Thursday, remaining below its 20-day moving average amid broader market weakness.

15 sept. 2026, 20:02 UTC

Jazz Pharmaceuticals PLC's acquisition of Actio Biosciences for $820 million enhances its epilepsy pipeline, but shares are lower today following an earlier peak.

11 sept. 2026, 20:02 UTC

UBS raised its price target on Jazz Pharmaceuticals to $337, maintaining a Buy rating amid confidence in growth prospects. Shares are trading higher today.

8 sept. 2026, 20:03 UTC

Jazz Pharmaceuticals PLC is declining amid broader pharmaceuticals sector weakness, breaking a recent trend of higher daily closes since Friday.

4 sept. 2026, 19:36 UTC

Jazz Pharmaceuticals PLC shares are lower today amid rising Treasury yields and strong labor market data, reflecting broader market trends.

3 sept. 2026, 21:21 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, reflecting ongoing pressure despite broader market strength and decreasing rate hike expectations.

2 sept. 2026, 19:46 UTC

Jazz Pharmaceuticals PLC shares are higher today, despite an earlier pullback. Broader market conditions include rising U.S. Treasury yields amid inflation concerns.

1 sept. 2026, 19:54 UTC

Jazz Pharmaceuticals shares are lower despite positive Phase 3 trial results for Ziihera, influenced by tightening monetary policy expectations and rising Treasury yields.

31 aug. 2026, 23:41 UTC

Jazz Pharmaceuticals PLC reported positive results from the HERIZON-GEA-01 trial for Ziihera, leading shares higher in after-hours trading.

28 aug. 2026, 20:02 UTC

Jazz Pharmaceuticals PLC shares are lower today, reversing a trend of higher closes. Broader market pressures include rising U.S. Treasury yields amid inflation concerns.

26 aug. 2026, 20:08 UTC

Jazz Pharmaceuticals PLC shares are lower following a $1 billion note offering and potential $225 million buyback, despite positive FDA approvals and target raises from analysts.

25 aug. 2026, 20:07 UTC

Jazz Pharmaceuticals rises on FDA approval of Ziihera for treating advanced HER2-positive gastroesophageal cancer. Bank of America sets price target at $307.

24 aug. 2026, 19:26 UTC

Jazz Pharmaceuticals shares are lower amid broader market sentiment influenced by geopolitical tensions. Ziihera's potential in the HER2+ market presents a growth opportunity.

22 aug. 2026, 00:02 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline since Friday's close, despite broader gains in major U.S. stocks.

21 aug. 2026, 20:06 UTC

Jazz Pharmaceuticals PLC shares are higher during Friday's session, reflecting strong upward momentum since Thursday's close, despite a recent pullback from session highs.

20 aug. 2026, 19:56 UTC

Jazz Pharmaceuticals PLC shares are lower amid a broader market decline following disappointing sales growth and guidance from Walmart. They remain below their 20-day moving average.

19 aug. 2026, 22:36 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline from regular trading, despite a broader recovery in equities.

18 aug. 2026, 20:03 UTC

Jazz Pharmaceuticals shares are trading higher, reflecting strength in the pharmaceuticals sector, despite a slight pullback from earlier session gains.

17 aug. 2026, 23:31 UTC

Jazz Pharmaceuticals PLC shares declined during after-market hours, reflecting broader market pressures from rising crude oil prices amid escalating U.S.-Iran tensions.

12 aug. 2026, 19:46 UTC

Jazz Pharmaceuticals shares are higher after Q2 revenue rose 16% to $1.21 billion, exceeding expectations. The company raised its full-year guidance to $4.68 billion.

11 aug. 2026, 22:46 UTC

Jazz Pharmaceuticals PLC shares advanced in after-market trading, diverging from broader market trends that closed lower amid rising crude oil prices.

10 aug. 2026, 19:56 UTC

Jazz Pharmaceuticals PLC to acquire Actio Biosciences for $820 million, enhancing its rare epilepsy portfolio. Shares are higher despite earlier session pullback.

7 aug. 2026, 19:36 UTC

Jazz Pharmaceuticals shares are higher today, reflecting broader market gains amid expectations the Federal Reserve may pause interest rate hikes.

6 aug. 2026, 19:21 UTC

Jazz Pharmaceuticals PLC shares are lower today, despite earlier gains. Mixed economic signals contribute to cautious sentiment ahead of the non-farm payrolls report.

5 aug. 2026, 19:36 UTC

Shares of Jazz Pharmaceuticals PLC are lower today, despite earlier gains. The company raised its full-year revenue guidance, driven by strong performance from Xywav.

4 aug. 2026, 20:04 UTC

Jazz Pharmaceuticals PLC shares rise as analysts upgrade price targets, following strong Q2 results that beat revenue estimates and boosted 2026 sales guidance.

3 aug. 2026, 23:02 UTC

Jazz Pharmaceuticals reported Q2 revenues of $1.208 billion, exceeding expectations. Shares advanced in after-market trading following the raised full-year guidance.

31 iul. 2026, 23:21 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market trading, pulled back from earlier session highs amid broader market declines, particularly in major tech stocks.

30 iul. 2026, 19:59 UTC

Jazz Pharmaceuticals shares are higher, reflecting broader market recovery amid significant gains in the technology sector. The stock is near the upper end of its one-month range.